Information  X 
Enter a valid email address

Ilika plc (IKA)

  Print          Annual reports

Thursday 08 April, 2021

Ilika plc

Appointment of Berenberg as Joint Corporate Broker

RNS Number : 7399U
Ilika plc
08 April 2021
 

 

Ilika plc

("Ilika", or the "Company")

 

Appointment of Berenberg as Joint Corporate Broker

 

Ilika (AIM: IKA) a pioneer in solid-state battery technology, announces the appointment of Berenberg as the Company's Joint Broker with immediate effect.

 

Berenberg will work alongside the Company's existing Nomad and Broker, Liberum Capital Limited.

 

For more information contact:

 

Ilika plc

 

 

www.ilika.com

Graeme Purdy, Chief Executive Officer

Via Walbrook PR

Steve Boydell, Finance Director






Liberum Capital Limited (Nomad and Joint Broker)

Tel: 020 3100 2000

Andrew Godber, Cameron Duncan, William Hall, Nikhil Varghese




Berenberg (Joint Broker)

Tel: 020 3207 7800

Emily Morris, Detlir Elezi,

Alamgir Ahmed, Milo Bonser

 

 





Walbrook PR Ltd

Tel: 020 7933 8780 /    [email protected]

Tom Cooper

Mob: 0797 122 1972

Lianne Cawthorne

Mob: 07584 391 303

Nick Rome

Mob: 07748 325 236

 

About Ilika:  

Ilika plc (AIM: IKA) is a pioneer in solid state battery technology with their innovative Stereax micro batteries designed for next-generation MedTech markets, and their Goliath large format batteries for the electric vehicle and consumer electronics markets. Ilika works closely with its ecosystem of partners to provide customisable Stereax micro batteries and develop its Goliath Wh-level solid state battery pouches and cells. The company is building a consortium of global expertise with its Goliath Leader Partnership program.

 

Find more about Ilika and their innovative solid state battery technology at  www.ilika.com  and on Twitter at @ilikaplc.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPEAKLXEAAFEFA

a d v e r t i s e m e n t